Kiniksa Pharmaceuticals (KNSA) Competitors

$17.10
+0.18 (+1.06%)
(As of 04/22/2024 ET)

KNSA vs. IRWD, AKRO, PCRX, DCPH, DAWN, ABCL, COLL, OCUL, VRNA, and XNCR

Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Akero Therapeutics (AKRO), Pacira BioSciences (PCRX), Deciphera Pharmaceuticals (DCPH), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Collegium Pharmaceutical (COLL), Ocular Therapeutix (OCUL), Verona Pharma (VRNA), and Xencor (XNCR). These companies are all part of the "medical" sector.

Kiniksa Pharmaceuticals vs.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Ironwood Pharmaceuticals received 341 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. However, 63.78% of users gave Kiniksa Pharmaceuticals an outperform vote while only 61.04% of users gave Ironwood Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Kiniksa PharmaceuticalsOutperform Votes
162
63.78%
Underperform Votes
92
36.22%
Ironwood PharmaceuticalsOutperform Votes
503
61.04%
Underperform Votes
321
38.96%

In the previous week, Kiniksa Pharmaceuticals had 2 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for Kiniksa Pharmaceuticals and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.33 beat Kiniksa Pharmaceuticals' score of 0.32 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiniksa Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 54.2% of Kiniksa Pharmaceuticals shares are held by company insiders. Comparatively, 13.1% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Kiniksa Pharmaceuticals currently has a consensus price target of $30.00, suggesting a potential upside of 75.49%. Ironwood Pharmaceuticals has a consensus price target of $19.80, suggesting a potential upside of 145.66%. Given Ironwood Pharmaceuticals' higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ironwood Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kiniksa Pharmaceuticals has a net margin of 5.11% compared to Ironwood Pharmaceuticals' net margin of -226.37%. Kiniksa Pharmaceuticals' return on equity of -6.12% beat Ironwood Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals5.11% -6.12% -5.20%
Ironwood Pharmaceuticals -226.37%-185.45%21.00%

Kiniksa Pharmaceuticals has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa Pharmaceuticals$270.26M4.47$14.08M$0.1894.97
Ironwood Pharmaceuticals$442.73M2.85-$1.00B-$6.51-1.24

Summary

Kiniksa Pharmaceuticals beats Ironwood Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KNSA vs. The Competition

MetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.21B$6.34B$4.74B$7.35B
Dividend YieldN/A3.11%5.55%3.98%
P/E Ratio94.9817.02258.4020.30
Price / Sales4.47304.232,587.9983.33
Price / CashN/A19.0131.8227.23
Price / Book2.745.424.564.22
Net Income$14.08M$138.04M$101.65M$213.35M
7 Day Performance-1.98%-3.00%-1.87%-1.08%
1 Month Performance-14.40%-9.23%-6.64%-4.99%
1 Year Performance46.61%-0.66%8.28%4.76%

Kiniksa Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IRWD
Ironwood Pharmaceuticals
4.1107 of 5 stars
$7.89
+1.3%
$19.80
+151.0%
-25.0%$1.24B$442.73M-1.21267
AKRO
Akero Therapeutics
3.5846 of 5 stars
$21.79
+0.3%
$39.00
+79.0%
-55.1%$1.23BN/A-7.6555Analyst Report
PCRX
Pacira BioSciences
4.9652 of 5 stars
$26.87
+1.3%
$49.50
+84.2%
-45.1%$1.25B$674.98M33.17712
DCPH
Deciphera Pharmaceuticals
3.3767 of 5 stars
$14.84
-0.4%
$23.00
+55.0%
-1.0%$1.20B$163.36M-6.48355Positive News
DAWN
Day One Biopharmaceuticals
2.1299 of 5 stars
$14.61
+5.5%
$40.60
+177.9%
+12.3%$1.28BN/A-6.14155Analyst Report
Insider Selling
News Coverage
Gap Up
ABCL
AbCellera Biologics
0.9572 of 5 stars
$4.05
-3.1%
$15.86
+291.5%
-44.4%$1.19B$38.03M-7.79586Positive News
COLL
Collegium Pharmaceutical
2.0333 of 5 stars
$35.40
+0.7%
$39.00
+10.2%
+50.6%$1.16B$566.77M30.00197
OCUL
Ocular Therapeutix
3.5793 of 5 stars
$7.79
-0.1%
$16.80
+115.7%
-21.1%$1.16B$58.44M-6.23267
VRNA
Verona Pharma
1.1513 of 5 stars
$16.20
+2.5%
$33.00
+103.7%
-32.6%$1.31B$460,000.00-23.4879
XNCR
Xencor
3.8628 of 5 stars
$18.92
-5.9%
$36.00
+90.3%
-36.7%$1.16B$168.34M-9.01280Gap Down

Related Companies and Tools

This page (NASDAQ:KNSA) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners